October 6, 2017
Favorable Pharmacokinetic and Safety Data for SPR741 Observed at Doses Exceeding the Anticipated Phase 2 Dose Range CAMBRIDGE, Mass., Oct. 03, 2017 (GLOBE NEWSWIRE) — Spero Therapeutics, Inc., a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for multi-drug resistant bacterial infections, today announced data from the Company’s Phase 1 single...


Robust operating profit and record level of funds for grants
18. April 2018
The Lundbeck Foundation enters partnership with
10. April 2018
Four neuroscientists receive The Brain Prize for crucial research on Alzheimer’s
6. March 2018


Lundbeckfonden Ventures

Lundbeckfonden Emerge